
In a large randomized, double-blind, placebo-controlled study that evaluated the general safety of the live herpes zoster vaccine (Zostavax, Merck) in adults aged 60 or older, the safety profile of ZOSTAVAX was similar to that of placebo with respect to serious adverse events.